OR WAIT null SECS
- About Us
- Advertise
- Editorial Information
- Contact Us
- Do Not Sell My Personal Information
- Privacy Policy
- Terms and Conditions
© 2021 MJH Life Sciences™ and BioPharm International. All rights reserved.
Is There a “New Normal” for Drug Quality?
Rita C. Peters is editorial director of BioPharm International, Pharmaceutical Technology, and Pharmaceutical Technology Europe.
With some FDA inspections on hold, will the US drug supply maintain its quality standards?
In February 2020, a report from FDA’s Office of Pharmaceutical Quality (OPQ) noted that, “Quite simply, the quality of our drug supply is better than ever before.” With some FDA inspections on hold, will the US drug supply maintain its quality standards? Plus, which new drug applications must now be filed as biologic license application?
Read this article in BioPharm International’s March 2020 Regulatory Sourcebook.
Article Details
BioPharm International
eBook: Regulatory Sourcebook and Reference, March 2020
March 2020
Pages: 4–5
Citation
When referring to this article, please cite it as R. Peters, “Is There a “New Normal” for Drug Quality?" BioPharm International Regulatory Sourcebook and Reference eBook (March 2020).
Related Content: